Evidence map›Paper›PMID 28816583›Full record

ArticlemAbs2017

Mammalian cell surface display for monoclonal antibody-based FACS selection of viral envelope proteins.

Tim-Henrik Bruun, Veronika Grassmann, Benjamin Zimmer, Benedikt Asbach, David Peterhoff, Alexander Kliche, Ralf Wagner

Open access · goldAbstract read
In one paragraph

Article in mAbs, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.7field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 14 citations in OpenAlex.

  1. A Synthetic Platform for Antibody Junctional Diversification Beyond Natural Constraints.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Article
  2. Article
  3. Multiplex, multimodal mapping of variant effects in secreted proteins.bioRxiv : the preprint server for biology · 2025
    Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Tim-Henrik Bruuna Institute of Medical Microbiology and Hygiene, Molecular Microbiology (Virology) , University Regensburg , Regensburg , Germany.
Veronika Grassmanna Institute of Medical Microbiology and Hygiene, Molecular Microbiology (Virology) , University Regensburg , Regensburg , Germany.
Benjamin Zimmera Institute of Medical Microbiology and Hygiene, Molecular Microbiology (Virology) , University Regensburg , Regensburg , Germany.
Benedikt Asbacha Institute of Medical Microbiology and Hygiene, Molecular Microbiology (Virology) , University Regensburg , Regensburg , Germany.
David Peterhoffa Institute of Medical Microbiology and Hygiene, Molecular Microbiology (Virology) , University Regensburg , Regensburg , Germany.
Alexander Klichea Institute of Medical Microbiology and Hygiene, Molecular Microbiology (Virology) , University Regensburg , Regensburg , Germany.
Ralf Wagnera Institute of Medical Microbiology and Hygiene, Molecular Microbiology (Virology) , University Regensburg , Regensburg , Germany.
Institute of Medical Microbiology and Hygiene · DEUniversity Hospital Regensburg · DE

Funding

Vaccine TechnologiesP01AI066287 · NIAID · NOVARTIS VACCINES AND DIAGNOSTICS, INC. · PI DAVIS, DAVID · 2006 to 2010
$21.3M
NIAID NIH HHS P01 AI066287
6 · The paper itself

Abstract

The elicitation of broadly and efficiently neutralizing antibodies in humans by active immunization is still a major obstacle in the development of vaccines against pathogens such as the human immunodeficiency virus (HIV), influenza virus, hepatitis C virus or cytomegalovirus. Here, we describe a mammalian cell surface display and monoclonal antibody (mAb)-mediated panning technology that allows affinity-based selection of envelope (Env) variants from libraries. To this end, we established an experimental setup featuring: 1) single and site specific integration of Env to link genotype and phenotype, 2) inducible Env expression to avoid cytotoxicity effects, 3) translational coupling of Env and enhanced green fluorescent protein expression to normalize for Env protein levels, and 4) display on HEK cells to ensure native folding and mammalian glycosylation. For proof of concept, we applied our method to a chimeric HIV-1 Env model library comprising variants with differential binding affinities to the V3-loop-directed mAbs 447-52D and HGN194. Fluorescence-activated cell sorting selectively enriched a high affinity variant up to 56- and 55-fold for 447-52D and HGN194, respectively, after only a single round of panning. Similarly, the low affinity variants for each antibody could be selectively enriched up to 237-fold. The binding profiles of membrane-bound gp145 and soluble gp140 chimeras showed identical affinity ranking, suggesting that the technology can guide the identification of Env variants with optimized antigenic properties for subsequent use as vaccine candidates. Finally, our mAb-based cellular display and selection strategy may also prove useful for the development of prophylactic vaccines against pathogens other than HIV.

Indexed as

Antibodies, MonoclonalAntibodies, NeutralizingFlow CytometryHEK293 CellsHumansViral Envelope ProteinsAntibodies, MonoclonalAntibodies, NeutralizingViral Envelope ProteinsHIV-1 envelopelibrarymammalian cell displayneutralizing antibodiespanning

Identifiers

PMID28816583
PMCPMC5627598
OpenAlexW2750508137

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.